161 related articles for article (PubMed ID: 37750443)
1. Chemotherapy-Induced Neoantigen Nanovaccines Enhance Checkpoint Blockade Cancer Immunotherapy.
Chen G; Li X; Li R; Wu K; Lei Z; Dai R; Roche K; Wang AZ; Min Y
ACS Nano; 2023 Oct; 17(19):18818-18831. PubMed ID: 37750443
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy-induced nanovaccines implement immunogenicity equivalence for improving cancer chemoimmunotherapy.
Li R; Hao Y; Roche K; Chen G; Pan W; Wang AZ; Min Y
Biomaterials; 2023 Oct; 301():122290. PubMed ID: 37643488
[TBL] [Abstract][Full Text] [Related]
3. Red blood cell-based vaccines for ameliorating cancer chemoimmunotherapy.
Su L; Hao Y; Li R; Pan W; Ma X; Weng J; Min Y
Acta Biomater; 2022 Dec; 154():401-411. PubMed ID: 36241013
[TBL] [Abstract][Full Text] [Related]
4. Monophosphoryl lipid A-assembled nanovaccines enhance tumor immunotherapy.
Li R; Hao Y; Pan W; Wang W; Min Y
Acta Biomater; 2023 Nov; 171():482-494. PubMed ID: 37708924
[TBL] [Abstract][Full Text] [Related]
5. A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists.
Baljon JJ; Kwiatkowski AJ; Pagendarm HM; Stone PT; Kumar A; Bharti V; Schulman JA; Becker KW; Roth EW; Christov PP; Joyce S; Wilson JT
ACS Nano; 2024 Mar; 18(9):6845-6862. PubMed ID: 38386282
[TBL] [Abstract][Full Text] [Related]
6. Self-Adjuvanted Molecular Activator (SeaMac) Nanovaccines Promote Cancer Immunotherapy.
Luo Z; He T; Liu P; Yi Z; Zhu S; Liang X; Kang E; Gong C; Liu X
Adv Healthc Mater; 2021 Apr; 10(7):e2002080. PubMed ID: 33336537
[TBL] [Abstract][Full Text] [Related]
7. Lymph node-targeted neoantigen nanovaccines potentiate anti-tumor immune responses of post-surgical melanoma.
Chu Y; Qian L; Ke Y; Feng X; Chen X; Liu F; Yu L; Zhang L; Tao Y; Xu R; Wei J; Liu B; Liu Q
J Nanobiotechnology; 2022 Apr; 20(1):190. PubMed ID: 35418151
[TBL] [Abstract][Full Text] [Related]
8. Nanovaccine Based on a Biepitope Antigen to Potentiate the Immunogenicity of a Neoantigen.
Chen S; Xu X; Zhang Y; Ye L; Zhang L; Li L; Chen G
ACS Macro Lett; 2023 Feb; 12(2):281-287. PubMed ID: 36752382
[TBL] [Abstract][Full Text] [Related]
9. RNA Origami Functions as a Self-Adjuvanted Nanovaccine Platform for Cancer Immunotherapy.
Yip T; Qi X; Yan H; Chang Y
ACS Nano; 2024 Feb; 18(5):4056-4067. PubMed ID: 38270089
[TBL] [Abstract][Full Text] [Related]
10. Co-delivery of Peptide Neoantigens and Stimulator of Interferon Genes Agonists Enhances Response to Cancer Vaccines.
Shae D; Baljon JJ; Wehbe M; Christov PP; Becker KW; Kumar A; Suryadevara N; Carson CS; Palmer CR; Knight FC; Joyce S; Wilson JT
ACS Nano; 2020 Aug; 14(8):9904-9916. PubMed ID: 32701257
[TBL] [Abstract][Full Text] [Related]
11. High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4
Hernandez R; LaPorte KM; Hsiung S; Santos Savio A; Malek TR
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34475132
[TBL] [Abstract][Full Text] [Related]
12. Stimuli-Responsive Nanoadjuvant Rejuvenates Robust Immune Responses to Sensitize Cancer Immunotherapy.
Huang R; Zhou P; Chen B; Zhu Y; Chen X; Min Y
ACS Nano; 2023 Nov; 17(21):21455-21469. PubMed ID: 37897704
[TBL] [Abstract][Full Text] [Related]
13. Nanovaccine that activates the NLRP3 inflammasome enhances tumor specific activation of anti-cancer immunity.
Manna S; Maiti S; Shen J; Weiss A; Mulder E; Du W; Esser-Kahn AP
Biomaterials; 2023 May; 296():122062. PubMed ID: 36863071
[TBL] [Abstract][Full Text] [Related]
14. Programming peptide-oligonucleotide nano-assembly for engineering of neoantigen vaccine with potent immunogenicity.
Xiang Z; Lu J; Rao S; Fu C; Yao Y; Yi Y; Ming Y; Sun W; Guo W; Chen X
Theranostics; 2024; 14(6):2290-2303. PubMed ID: 38646651
[No Abstract] [Full Text] [Related]
15. Nanovaccines for cancer immunotherapy.
Zhang Y; Lin S; Wang XY; Zhu G
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Sep; 11(5):e1559. PubMed ID: 31172659
[TBL] [Abstract][Full Text] [Related]
16. Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy.
Su T; Cheng F; Qi J; Zhang Y; Zhou S; Mei L; Fu S; Zhang F; Lin S; Zhu G
Adv Sci (Weinh); 2022 Aug; 9(23):e2201895. PubMed ID: 35712773
[TBL] [Abstract][Full Text] [Related]
17. A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer.
Ni Q; Zhang F; Liu Y; Wang Z; Yu G; Liang B; Niu G; Su T; Zhu G; Lu G; Zhang L; Chen X
Sci Adv; 2020 Mar; 6(12):eaaw6071. PubMed ID: 32206706
[TBL] [Abstract][Full Text] [Related]
18. Advances in personalized neoantigen vaccines for cancer immunotherapy.
Sun C; Xu S
Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
[TBL] [Abstract][Full Text] [Related]
19. Hybrid Membrane Nanovaccines Combined with Immune Checkpoint Blockade to Enhance Cancer Immunotherapy.
Zhao P; Xu Y; Ji W; Li L; Qiu L; Zhou S; Qian Z; Zhang H
Int J Nanomedicine; 2022; 17():73-89. PubMed ID: 35027827
[TBL] [Abstract][Full Text] [Related]
20. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]